KNSA
NASDAQ · Biotechnology
Kiniksa Pharmaceuticals Inte
$78.13
+0.89 (+1.15%)
Financial Highlights (FY 2026)
Revenue
687.48M
Net Income
59.87M
Gross Margin
88.5%
Profit Margin
8.7%
Rev Growth
+45.5%
D/E Ratio
—
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | 88.5% | 88.5% | 29.3% | 29.3% |
| Operating Margin | 11.4% | 10.3% | -19.5% | -19.3% |
| Profit Margin | 8.7% | 8.3% | -18.5% | -21.6% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 687.48M | 472.66M | 434.64M | 442.76M |
| Gross Profit | 608.69M | 418.49M | 127.23M | 129.60M |
| Operating Income | 78.37M | 48.49M | -84,738,129 | -85,375,508 |
| Net Income | 59.87M | 37.05M | -80,259,876 | -95,460,191 |
| Gross Margin | 88.5% | 88.5% | 29.3% | 29.3% |
| Operating Margin | 11.4% | 10.3% | -19.5% | -19.3% |
| Profit Margin | 8.7% | 8.3% | -18.5% | -21.6% |
| Rev Growth | +45.5% | +45.5% | +6.7% | -5.5% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 0 | 0 | 1.61B | 1.43B |
| Total Equity | — | — | 2.13B | 1.91B |
| D/E Ratio | — | — | 0.75 | 0.75 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | 79.93M | 52.20M | -90,838,119 | -106,481,438 |
| Free Cash Flow | — | — | -118,111,706 | -105,818,031 |